All Stories

  1. Long-term Impact of Cenobamate on Cognition in Patients with Drug-Resistant Focal Epilepsy: Outcomes from an Exploratory Real-World Study
  2. Effectiveness and safety of early add‐on therapy with brivaracetam in patients with poorly controlled focal seizures in routine clinical practice: BRIV‐add study
  3. Tratamiento de la crisis epiléptica en el ámbito no sanitario: tiempo de tratar (TT)
  4. Inflammatory Drug-Resistant Epilepsy Index (IDREI) as a Molecular Compound Biomarker in Focal Epilepsies
  5. Proposal of an Inflammatory Drug‐Resistant Epilepsy Index (Idrei) as Molecular Composed Biomarker in Focal Epilepsies
  6. Impact of TNF inhibitors on inflammation-associated cognitive dysfunction in patients with rheumatoid arthritis: a prospective analysis
  7. Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy
  8. Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease
  9. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  10. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
  11. Biomarkers of Neuroinflammation and Epileptogenesis: A Systematic Review
  12. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats
  13. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus
  14. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions
  15. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study
  16. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study
  17. Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol
  18. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
  19. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
  20. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  21. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  22. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
  23. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
  24. Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
  25. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
  26. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy
  27. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review
  28. Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis
  29. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  30. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  31. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
  32. The cognitive and psychiatric subacute impairment in severe Covid-19
  33. Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?
  34. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  35. Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with Drug-Resistant Temporal Lobe Epilepsy of Unknown Etiology
  36. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
  37. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  38. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
  39. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain
  40. Efectos de la pandemia por Covid-19 sobre la calidad de vida de los pacientes con Esclerosis Lateral Amiotrófica
  41. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  42. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis
  43. GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus
  44. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
  45. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  46. Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic
  47. Miller‐Fisher syndrome after SARS‐CoV‐2 infection
  48. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
  49. Reader response: Neurologic complications of coronavirus infections
  50. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  51. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report
  52. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2
  53. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa
  54. Incidence and case fatality rate of COVID-19 in patients with active epilepsy
  55. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?
  56. ¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave
  57. Response to immunotherapy in anti‐IgLON5 disease: A systematic review
  58. Evaluación prequirúrgica mediante resonancia magnética funcional en pacientes con tumores neuroepiteliales disembrioplásicos: una serie de casos
  59. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit
  60. Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene
  61. Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunológico: primer caso secundario a avelumab y revisión de casos previamente publicados
  62. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN
  63. Consenso Delphi EPICON: recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbazepina en epilepsia
  64. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review
  65. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures
  66. Estudio observacional multicéntrico español sobre el empleo de fármacos antiepilépticos en consultas de neurología
  67. Epidemiología de la epilepsia en España y Latinoamérica
  68. Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients
  69. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
  70. Awagrafia
  71. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
  72. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa
  73. Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
  74. Adhesión al tratamiento con levetiracetam: estudio observacional retrospectivo no intervencionista
  75. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
  76. Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
  77. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
  78. Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study
  79. Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015
  80. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study
  81. Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study
  82. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
  83. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
  84. Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness
  85. Spatial recognition memory in a virtual reality task is altered in refractory temporal lobe epilepsy
  86. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES)
  87. Validación en castellano de un cuestionario breve útil para cribado epidemiológico de epilepsia en España: Cuestionario EPIBERIA
  88. Acetato de eslicarbazepina en la práctica clínica. Resultados de eficacia y seguridad
  89. Zonisamida en el tratamiento de la epilepsia: revisión de la bibliografía desde la terapia añadida a la monoterapia
  90. Consenso de las Recomendaciones de Actuación diagnóstica y Terapéutica sobre Epilepsia resistente a fármacos antiepilépticos en España (Consenso RATE-España)
  91. Predictive model for refractoriness in Temporal Lobe Epilepsy based on clinical and diagnostic test data
  92. Cajal’s first steps in scientific research
  93. Spatial navigation impairment in patients with refractory temporal lobe epilepsy: Evidence from a new virtual reality-based task
  94. Factores vinculados a la adhesión al tratamiento en pacientes con epilepsia refractaria y no refractaria
  95. Antiepileptic treatment in patients with epilepsy and other comorbidities
  96. Vohwinkel Syndrome secondary to missense mutation D66H in GJB2 gene (connexin 26) can include epileptic manifestations
  97. Amnesia topográfica transitoria: descripción de una serie de ocho casos
  98. Possible case of peripheral osmotic demyelination syndrome
  99. Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain
  100. Guía de práctica clínica de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis epilépticas sintomáticas agudas
  101. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre prescripción de fármacos antiepilépticos genéricos
  102. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia: recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico
  103. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia
  104. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)
  105. Possible case of peripheral osmotic demyelination syndrome
  106. Incidencia de ictus en España. Bases metodológicas del estudio Iberictus
  107. Pseudomigraña con pleocitosis y la ‘invisibilidad’ de las descripciones originales en castellano
  108. Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs
  109. Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS
  110. Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review
  111. Menstrual Tension-Type Headache: Evidence for Its Existence.
  112. A transcranial doppler study in interictal migraine and tension-type headache
  113. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  114. Encefalomielitis aguda diseminada por picadura de himenóptero
  115. Avances en el conocimiento de la etiología y la fisiopatología de las epilepsias reflejas
  116. Cirugía de la epilepsia del lóbulo temporal: ¿es suficiente eliminar las crisis?
  117. Trombólisis en el ictus: la accesibilidad sin garantía de seguridad es insostenible
  118. Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'
  119. The Red Ear Syndrome: Five New Cases
  120. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño
  121. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales
  122. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico
  123. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: IV. Principios generales de politerapia antiepiléptica y estrategias terapéuticas en epilepsia refractaria
  124. Doppler transcraneal en el diagnóstico de fístula arteriovenosa pulmonar
  125. Infarto maligno de la arteria cerebral media: ¿tratamiento médico o quirúrgico?
  126. Hemorragia cerebral múltiple y antiagregantes plaquetarios
  127. Ring chromosome 20 epilepsy syndrome in children: Electroclinical features
  128. Paciente de 45 años con epilepsia refractaria del lóbulo temporal desde la infancia
  129. Epilepsia refractaria del adulto
  130. Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia
  131. Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia
  132. Epilepsia parcial refractaria a tratamiento médico y lesión porencefálica occipital
  133. Controversias en torno a los nuevos fármacos antiepilépticos
  134. El diagnóstico de la enfermedad cervical espondilótica: una revisión basada en la evidencia
  135. Caracterización epidemiológica de la epilepsia del adulto subsidiaria de ingreso hospitalario
  136. Pseudotumor inflamatorio: diagnóstico diferencial de los tumores del IV ventrículo
  137. Cromosoma 20 en anillo: ¿Una canalopatía epiléptica?
  138. Ischemic Stroke following Cisplatin and 5-Fluorouracil Therapy: A Transcranial Doppler Study
  139. Descripción histórica de la asociación de macroorquídia, retraso mental y dismorfia craneal en varones (Síndrome del cromosoma X frágil) por A. B. Richerand
  140. Hemodinámica cerebral en el síndrome de pseudomigraña con pleocitosis de LCR: un estudio Doppler transcraneal
  141. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética
  142. Correlación genotipo-fenotipo en la distrofia miotónica y predicción de la gravedad clínica
  143. Hemiatrofia facial progresiva de Parry-Romberg: consideraciones patogénicas y evolutivas a propósito de un caso con seguimiento prolongado
  144. Esclerosis temporal mesial (II): manifestaciones clínicas y estudios complementarios
  145. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases
  146. Mediterranean spotted fever with central and peripheral neurological complications